Spero Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Spero Therapeutics, Inc. (SPRO) had Debt Securities, Available-for-sale, Amortized Cost of $49.86 million as of 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-03-30
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $49.86M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $33.82M.
- 2021-09-30: Debt Securities, Available-for-sale, Amortized Cost $10.56M.
- 2021-06-30: Debt Securities, Available-for-sale, Amortized Cost $27.66M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-03-31 | $49.86M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $33.82M 10-K · filed 2023-03-30 |
| 2021-09-30 | $10.56M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $27.66M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $38.64M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $41.70M 10-K · filed 2022-03-31 |
| 2020-09-30 | $2.00M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $6.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $24.50M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $52.30M 10-K · filed 2021-03-11 |
| 2019-09-30 | $48.24M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $32.27M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $57.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $81.39M 10-Q · filed 2019-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |